- Conditions
- Sickle Cell Anemia
- Interventions
- Regadenoson, Placebo
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 10 Years to 70 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 12
- States / cities
- Oakland, California • Chicago, Illinois • Baltimore, Maryland + 7 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 992
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Aplastic Anemia, Paroxysmal Hemoglobinuria, Nocturnal
- Interventions
- cyclophosphamide, filgrastim
- Drug
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- Up to 70 Years
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1996 – 2008
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Sickle Cell Disease
- Interventions
- Voxelotor, Bupropion, Repaglinide, Flurbiprofen, Omeprazole, Midazolam, Metformin, Furosemide, Rosuvastatin
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 44 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Paroxysmal Nocturnal Hemoglobinuria (PNH)
- Interventions
- Ravulizumab, Eculizumab
- Biological
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- Not listed
- Enrollment
- 272 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Whittier, California • Fort Worth, Texas
- Conditions
- ABO Incompatibility, Hemolytic Disease of Newborn, Neonatal Jaundice, Neonatal Hyperbilirubinemia
- Interventions
- Not listed
- Lead sponsor
- State University of New York - Upstate Medical University
- Other
- Eligibility
- Up to 28 Days
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 2
- States / cities
- Syracuse, New York
- Conditions
- Sickle Cell Disease
- Interventions
- Plerixafor
- Drug
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Sickle Cell Disease
- Interventions
- Assessment
- Other
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- 12 Years to 30 Years
- Enrollment
- 55 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- Sickle Cell Anemia
- Interventions
- Not listed
- Lead sponsor
- Ann & Robert H Lurie Children's Hospital of Chicago
- Other
- Eligibility
- 8 Years to 21 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2015
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Sickling Disorder Due to Hemoglobin S
- Interventions
- 131I-apamistmab, Sirolimus, Campath, Total Body Irradiation, Exchange Transfusion, Planar gamma imaging
- Drug · Radiation · Procedure
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 12 Years to 50 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Hemoglobinopathies, Anemia, Sickle Cell, Hemoglobin SC Disease, Thalassemia, Thalassemia Major
- Interventions
- Busulfan, Fludarabine, FK506, Prednisone
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2003
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Sickle Cell Disease, Quality of Life, Stigma, Social, Disease Self-Management
- Interventions
- Not listed
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 102 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Sickle Cell Disease
- Interventions
- SuCCESs
- Behavioral
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland
- Conditions
- Sickle Cell Anemia, Pulmonary Hypertension
- Interventions
- Data Collection
- Other
- Lead sponsor
- Namita Sood
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 209 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Atypical Hemolytic Uremic Syndrome (aHUS)
- Interventions
- Not listed
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- Not listed
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 12
- States / cities
- Dunwoody, Georgia • Chicago, Illinois • Portland, Maine + 9 more
- Conditions
- Sickle Cell Disease, Cognitive Impairment, Adolescent Behavior, Self Efficacy, Health-Related Behavior, Coping Skills
- Interventions
- CREADY (Cognitive-Remediation of Executive and Adaptive Deficits in Youth)
- Behavioral
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 10 Years to 18 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Anemia, Sickle Cell
- Interventions
- GBT440
- Drug
- Lead sponsor
- Global Blood Therapeutics
- Industry
- Eligibility
- 18 Years to 55 Years · Male only
- Enrollment
- 7 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Child, Only, Brain Diseases, Sickle Cell Disease, Anemia, Sickle Cell
- Interventions
- Carbon Dioxide
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 4 Years to 21 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Sickle Cell Disease, Sickle Cell Anemia, Osteonecrosis, Ischemic Necrosis, Avascular Necrosis
- Interventions
- Alendronate Sodium
- Drug
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Anemia, Sickle Cell
- Interventions
- Not listed
- Lead sponsor
- Children's Mercy Hospital Kansas City
- Other
- Eligibility
- 8 Years to 18 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005
- U.S. locations
- 1
- States / cities
- Kansas City, Missouri
- Conditions
- Sickle Cell Disease, Sickle Cell Anemia
- Interventions
- Biotin label
- Drug
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Sickle Cell Disease
- Interventions
- AG-348
- Drug
- Lead sponsor
- National Institutes of Health Clinical Center (CC)
- NIH
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Sickle Cell Disease
- Interventions
- Not listed
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- 10 Years to 18 Years · Female only
- Enrollment
- 440 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2034
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- Heart Surgery, Blood Transfusion, Hemolysis
- Interventions
- blood sampling
- Other
- Lead sponsor
- Boston Children's Hospital
- Other
- Eligibility
- 0 Years to 17 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Sickle Cell Disease, Thalassemia, Pediatric Cancer
- Interventions
- Red Blood Cell (RBC) Transfusion
- Biological
- Lead sponsor
- Westat
- Other
- Eligibility
- Not listed
- Enrollment
- 157 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 9
- States / cities
- Oakland, California • San Francisco, California • Boston, Massachusetts + 2 more